Skip to content
OpenCapital
Get started

Relay Therapeutics, Inc. RLAY Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$3.0MMiss by $2.6M
EPS-$0.41Miss by $0.06
Revenue estimate$5.6M
EPS estimate-$0.35

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$960.0K
EPS estimate-$0.41

Financials

Q1 2026

Income statement

See full
Revenue$3.0M-60.9%
Operating income-$78.6M+7.4%
Net income-$73.3M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$204.6M+119%
Total debt$31.6M-33.1%
Total equity$642.2M-10.9%
Total assets$699.6M-12.5%

Cash flow

See full
Operating cash flow-$51.1M+30.2%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$4.06B+540%
Enterprise value$3.89B+601%
P/S380.5×+305×

Profitability

See full
Operating margin-2,776.6%-820pp
Net margin-2,554.1%-745pp

Returns & leverage

See full
Return on equity-40%-4.3pp
Debt / equity0×0.0×
Current ratio22.1×+2.2×

Versus estimates

Revenue

Q1 2026$3.0MMiss by $2.6M
Q4 2025$7.0MBeat by $2.0MQ2 2025$677.0KBeat by $662.7KQ1 2025$7.7MBeat by $3.9M

Diluted EPS

Q1 2026-$0.41Miss by $0.06
Q4 2025-$0.32Beat by $0.06Q3 2025-$0.43Miss by $0.04Q2 2025-$0.41Beat by $0.08Q1 2025-$0.46Beat by $0.04Q4 2024-$0.45Beat by $0.12

Ask the moment Relay Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Relay Therapeutics, Inc. report Q1 2026 earnings?
Relay Therapeutics, Inc. (RLAY) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Relay Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Relay Therapeutics, Inc. reported revenue of $3.0M and eps of $-0.41 for Q1 2026.
Did Relay Therapeutics, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $5.6M by $2.6M. EPS missed the consensus estimate of $-0.35 by $0.06.
How did Relay Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 60.9% from $7.7M a year earlier and eps grew 10.9% from $-0.46.
Where can I find Relay Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-206398) and the 10-Q periodic report (0001193125-26-206454) directly on SEC EDGAR. The filing index links above go to sec.gov.